{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T19:07:44Z","timestamp":1771355264079,"version":"3.50.1"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2017,5,2]],"date-time":"2017-05-02T00:00:00Z","timestamp":1493683200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,6,1]]},"DOI":"10.1093\/cid\/cix198","type":"journal-article","created":{"date-parts":[[2017,5,2]],"date-time":"2017-05-02T10:33:15Z","timestamp":1493721195000},"page":"1557-1563","source":"Crossref","is-referenced-by-count":46,"title":["Pharmacodynamics of Isavuconazole for Invasive Mold Disease: Role of Galactomannan for Real-Time Monitoring of Therapeutic Response"],"prefix":"10.1093","volume":"64","author":[{"given":"Laura L.","family":"Kovanda","sequence":"first","affiliation":[{"name":"Antimicrobial Pharmacodynamics and Therapeutics, Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, United Kingdom;"},{"name":"Astellas Pharma Global Development, Inc, Northbrook, Illinois;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruwanthi","family":"Kolamunnage-Dona","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Institute of Translational Medicine, University of Liverpool, United Kingdom;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Neely","sequence":"additional","affiliation":[{"name":"Laboratory of Applied Pharmacokinetics and Bioinformatics, Saban Research Institute, and Division of Pediatric Infectious Diseases, Children\u2019s Hospital Los Angeles, University of Southern California; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johan","family":"Maertens","sequence":"additional","affiliation":[{"name":"Universitaire Ziekenhuizen, Leuven, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Misun","family":"Lee","sequence":"additional","affiliation":[{"name":"Astellas Pharma Global Development, Inc, Northbrook, Illinois;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William W.","family":"Hope","sequence":"additional","affiliation":[{"name":"Antimicrobial Pharmacodynamics and Therapeutics, Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, United Kingdom;"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2017,5,2]]},"reference":[{"key":"key\n\t\t\t\t20180328154909_CIT0001","first-page":"w14281","article-title":"Common invasive fungal diseases: an overview of invasive candidiasis, aspergillosis, cryptococcosis, and Pneumocystis pneumonia","volume":"146","author":"Schmiedel","year":"2016","journal-title":"Swiss Med Wkly"},{"key":"key\n\t\t\t\t20180328154909_CIT0002","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/ciw326","article-title":"Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America","volume":"63","author":"Patterson","year":"2016","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180328154909_CIT0003","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1111\/1469-0691.12426","article-title":"Management and diagnostic guidelines for fungal diseases in infectious diseases and clinical microbiology: critical appraisal","volume":"19","author":"Leroux","year":"2013","journal-title":"Clin Microbiol Infect"},{"key":"key\n\t\t\t\t20180328154909_CIT0004","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/j.1469-0691.2008.01984.x","article-title":"Liposomal amphotericin B: what is its role in 2008?","volume":"14","author":"Lanternier","year":"2008","journal-title":"Clin Microbiol Infect"},{"key":"key\n\t\t\t\t20180328154909_CIT0005","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.jinf.2014.01.007","article-title":"Micafungin for the treatment of invasive aspergillosis","volume":"68","author":"Enoch","year":"2014","journal-title":"J Infect"},{"key":"key\n\t\t\t\t20180328154909_CIT0006","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1038\/bmt.2009.334","article-title":"Caspofungin first-line therapy for invasive aspergillosis in allogeneic hematopoietic stem cell transplant patients: an European Organisation for Research and Treatment of Cancer study","volume":"45","author":"Herbrecht","year":"2010","journal-title":"Bone Marrow Transplant"},{"key":"key\n\t\t\t\t20180328154909_CIT0007","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.ijantimicag.2014.05.019","article-title":"Voriconazole pharmacokinetics and exposure-response relationships: assessing the links between exposure, efficacy and toxicity","volume":"44","author":"Dolton","year":"2014","journal-title":"Int J Antimicrob Agents"},{"key":"key\n\t\t\t\t20180328154909_CIT0008","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1097\/QCO.0000000000000005","article-title":"Azole resistance in Aspergillus fumigatus: a growing public health concern","volume":"26","author":"Vermeulen","year":"2013","journal-title":"Curr Opin Infect Dis"},{"key":"key\n\t\t\t\t20180328154909_CIT0009","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1093\/infdis\/jis372","article-title":"Pharmacodynamics of voriconazole in a dynamic in vitro model of invasive pulmonary aspergillosis: implications for in vitro susceptibility breakpoints","volume":"206","author":"Jeans","year":"2012","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20180328154909_CIT0010","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.1128\/AAC.02665-15","article-title":"Pharmacokinetics and concentration-dependent efficacy of isavuconazole for treatment of experimental invasive pulmonary aspergillosis","volume":"60","author":"Petraitis","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180328154909_CIT0011","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1128\/AAC.04723-14","article-title":"Pharmacodynamics of amphotericin B deoxycholate, amphotericin B lipid complex, and liposomal amphotericin B against Aspergillus fumigatus","volume":"59","author":"Al-Nakeeb","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180328154909_CIT0012","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1093\/cid\/cir441","article-title":"Earlier response assessment in invasive aspergillosis based on the kinetics of serum Aspergillus galactomannan: proposal for a new definition","volume":"53","author":"Nou\u00e9r","year":"2011","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180328154909_CIT0013","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1002\/cncr.22863","article-title":"Serum Aspergillus galactomannan antigen values strongly correlate with outcome of invasive aspergillosis: a study of 56 patients with hematologic cancer","volume":"110","author":"Woods","year":"2007","journal-title":"Cancer"},{"key":"key\n\t\t\t\t20180328154909_CIT0014","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1086\/528714","article-title":"Strong correlation between serum Aspergillus galactomannan index and outcome of aspergillosis in patients with hematological cancer: clinical and research implications","volume":"46","author":"Miceli","year":"2008","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180328154909_CIT0015","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1002\/cncr.24022","article-title":"Galactomannan serves as a surrogate endpoint for outcome of pulmonary invasive aspergillosis in neutropenic hematology patients","volume":"115","author":"Maertens","year":"2009","journal-title":"Cancer"},{"key":"key\n\t\t\t\t20180328154909_CIT0016","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/S0140-6736(15)01159-9","article-title":"Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial","volume":"387","author":"Maertens","year":"2016","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20180328154909_CIT0017","doi-asserted-by":"crossref","first-page":"4568","DOI":"10.1128\/AAC.00514-16","article-title":"Isavuconazole population pharmacokinetic analysis using nonparametric estimation in patients with invasive fungal disease (results from the VITAL Study)","volume":"60","author":"Kovanda","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180328154909_CIT0018","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1097\/FTD.0b013e31825c4ba6","article-title":"Accurate detection of outliers and subpopulations with Pmetrics, a nonparametric and parametric pharmacometric modeling and simulation package for R","volume":"34","author":"Neely","year":"2012","journal-title":"Ther Drug Monit"},{"key":"key\n\t\t\t\t20180328154909_CIT0019","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1128\/AAC.03023-15","article-title":"Pharmacodynamics of voriconazole in children: further steps along the path to true individualized therapy","volume":"60","author":"Huurneman","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180328154909_CIT0020","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1093\/biostatistics\/1.4.465","article-title":"Joint modelling of longitudinal measurements and event time data","volume":"1","author":"Henderson","year":"2000","journal-title":"Biostatistics"},{"key":"key\n\t\t\t\t20180328154909_CIT0021","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.1200\/JCO.2009.25.0654","article-title":"Basic concepts and methods for joint models of longitudinal and survival data","volume":"28","author":"Ibrahim","year":"2010","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t20180328154909_CIT0022","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1093\/ije\/dyu262","article-title":"Joint modelling of repeated measurement and time-to-event data: an introductory tutorial","volume":"44","author":"Asar","year":"2015","journal-title":"Int J Epidemiol"},{"key":"key\n\t\t\t\t20180328154909_CIT0023","volume-title":"Exposure\u2013response analysis of isavuconazole in patients with disease caused by Aspergillus species or other filamentous fungi","author":"Desai","year":"2015"},{"key":"key\n\t\t\t\t20180328154909_CIT0024","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1086\/339324","article-title":"Invasive aspergillosis in allogeneic stem cell transplant recipients: increasing antigenemia is associated with progressive disease","volume":"34","author":"Boutboul","year":"2002","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180328154909_CIT0025","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1128\/JCM.06513-11","article-title":"Early serum galactomannan trend as a predictor of outcome of invasive aspergillosis","volume":"50","author":"Chai","year":"2012","journal-title":"J Clin Microbiol"},{"key":"key\n\t\t\t\t20180328154909_CIT0026","doi-asserted-by":"crossref","first-page":"e90176","DOI":"10.1371\/journal.pone.0090176","article-title":"Voriconazole or amphotericin B as primary therapy yields distinct early serum galactomannan trends related to outcomes in invasive aspergillosis","volume":"9","author":"Chai","year":"2014","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t20180328154909_CIT0027","doi-asserted-by":"crossref","first-page":"e0129022","DOI":"10.1371\/journal.pone.0129022","article-title":"Correlation between circulating fungal biomarkers and clinical outcome in invasive aspergillosis","volume":"10","author":"Neofytos","year":"2015","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t20180328154909_CIT0028","article-title":"Exposure-safety analysis of isavuconazole in patients from SECURE study with disease caused by Aspergillus species or other filamentous fungi","author":"Desai","year":"2015"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/64\/11\/1557\/17844296\/cix198.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,3,29]],"date-time":"2018-03-29T02:49:56Z","timestamp":1522291796000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/64\/11\/1557\/3788535"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,2]]},"references-count":28,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2017,5,2]]},"published-print":{"date-parts":[[2017,6,1]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/cix198","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2017,6,1]]},"published":{"date-parts":[[2017,5,2]]}}}